FDA Accepts NDA Application for Troriluzole as Potential First Treatment for Spinocerebellar Ataxia

Published Date: 13 Feb 2025

Troriluzole, a new chemical entity and third-generation novel prodrug that modulates glutamate, would become the first approved agent for SCA, pending the FDA’s clearance.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Boom in ADHD Coaching Has Few Rules

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

4.

Medicaid expansion tied to smaller declines in early-stage cancer detection

5.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot